Ozureprubart

Monoclonal antibody

Also known as GSK6775388

Automated registry profile: compiled from public clinical-trial and regulatory records; not yet individually analyst-verified.

—no registered trials

Evidence outlook

No clinical trials on ClinicalTrials.gov

No clinical trial of this drug is registered on ClinicalTrials.gov, so there is nothing to grade. Studies run outside that registry are not tracked here.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded.

No registered studies found. Not yet ingested, or none registered.

Competitive landscape

1 other tracked programme targets this mechanism.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Ozureprubart: this drugStage not on recordMonoclonal antibodyIgEnot yet gradedNo reviewed efficacy summary
Omalizumab (Xolair)
Approved(overall)
Monoclonal antibodyIgE (immunoglobulin E), IgEPartial signal
NCT03881696: Number of Participants by Stage 1 Treatment Assignment, Omalizumab Versus Placebo, Who Successfully Consume a Single Dose of ≥600 mg of Peanut Protein Without Dose-Limiting Symptoms During the DBPCFC Conducted at the End of Treatment Stage 1 (During the DBPCFC at the end of Stage 1: 16 to 20 weeks after Stage 1 treatment initiation): Omalizumab — Success: 79 Participants; Failure: 39 Participants | Placebo for Omalizumab — Success: 4 Participants; Failure: 55 Participants
NCT01287117: Change From Baseline to Week 12 in the Weekly Itch Severity Score (Baseline to Week 12): Placebo -3.63 Units on a scale (Standard Deviation 5.22) | Omalizumab 75 mg -6.46 Units on a scale (Standard Deviation 6.14) | Omalizumab 150 mg -6.66 Units on a scale (Standard Deviation 6.28) | Omalizumab 300 mg -9.4 Units on a scale (Standard Deviation 5.73)

Upcoming events

No upcoming readouts on record for this asset.